Arcus Biosciences, Inc. (RCUS)

USD 9.12

(5.8%)

Net Income Summary of Arcus Biosciences, Inc.

Arcus Biosciences, Inc.'s latest annual net income in 2023 was -307 Million USD , down -14.98% from previous year.
Arcus Biosciences, Inc.'s latest quarterly net income in 2024 Q2 was -93 Million USD , down -2225.0% from previous quarter.
Arcus Biosciences, Inc. reported an annual net income of -267 Million USD in 2022, down -603.77% from previous year.
Arcus Biosciences, Inc. reported an annual net income of 53 Million USD in 2021, up 145.42% from previous year.
Arcus Biosciences, Inc. reported a quarterly net income of -4 Million USD for 2024 Q1, up 95.06% from previous quarter.
Arcus Biosciences, Inc. reported a quarterly net income of -75 Million USD for 2023 Q2, up 6.25% from previous quarter.

Annual Net Income Chart of Arcus Biosciences, Inc. (2023 - 2016)

Historical Annual Net Income of Arcus Biosciences, Inc. (2023 - 2016)

Year	Net Income	Net Income Growth
2023	-307 Million USD	-14.98%
2022	-267 Million USD	-603.77%
2021	53 Million USD	145.42%
2020	-116.67 Million USD	-53.66%
2019	-75.93 Million USD	-53.11%
2018	-49.59 Million USD	6.57%
2017	-53.08 Million USD	-195.39%
2016	-17.97 Million USD	0.0%

Year	Net Income	Net Income Growth
2024 Q2	-93 Million USD	-2225.0%
2024 Q1	-4 Million USD	95.06%
2023 Q2	-75 Million USD	6.25%
2023 FY	-307 Million USD	-14.98%
2023 Q1	-80 Million USD	-19.41%
2023 Q3	-71 Million USD	5.33%
2023 Q4	-81 Million USD	-14.08%
2022 Q2	-64.28 Million USD	5.46%
2022 Q4	-66.99 Million USD	-10.85%
2022 FY	-267 Million USD	-603.77%
2022 Q1	-67.99 Million USD	-124.34%
2022 Q3	-60.44 Million USD	5.98%
2021 Q1	-72.59 Million USD	-40.0%
2021 FY	53 Million USD	145.42%
2021 Q2	-75.97 Million USD	-4.65%
2021 Q4	279.36 Million USD	458.28%
2021 Q3	-77.97 Million USD	-2.64%
2020 FY	-116.67 Million USD	-53.66%
2020 Q1	-27.75 Million USD	-67.21%
2020 Q2	-45.07 Million USD	-62.41%
2020 Q3	1.82 Million USD	104.04%
2020 Q4	-51.85 Million USD	-2945.94%
2019 Q4	-16.59 Million USD	25.74%
2019 Q3	-22.35 Million USD	20.43%
2019 Q2	-28.09 Million USD	-58.97%
2019 Q1	-17.67 Million USD	-43.72%
2019 FY	-75.93 Million USD	-53.11%
2018 Q3	-10.81 Million USD	20.11%
2018 FY	-49.59 Million USD	6.57%
2018 Q2	-13.53 Million USD	-4.47%
2018 Q1	-12.95 Million USD	1.94%
2018 Q4	-12.29 Million USD	-13.72%
2017 Q1	-7.2 Million USD	0.0%
2017 FY	-53.08 Million USD	-195.39%
2017 Q4	-13.21 Million USD	42.87%
2017 Q3	-23.12 Million USD	-142.12%
2017 Q2	-9.55 Million USD	-32.64%
2016 FY	-17.97 Million USD	0.0%

Peer Net Income Comparison of Arcus Biosciences, Inc.

Name	Net Income	Net Income Difference
ADC Therapeutics SA	-240.05 Million USD	-27.888%
Alto Neuroscience, Inc.	-36.3 Million USD	-745.614%
Annovis Bio, Inc.	-56.2 Million USD	-446.221%
Biohaven Pharmaceutical Holding Company Ltd.	-408.16 Million USD	24.786%
Ginkgo Bioworks Holdings, Inc.	-892.86 Million USD	65.616%
Nuvation Bio Inc.	-75.8 Million USD	-305.003%
Nuvation Bio Inc.	-75.8 Million USD	-305.003%
Zymeworks Inc.	-118.67 Million USD	-158.692%